74 not yet recruiting, 66 unknown, 46 recruiting, 33 completed. 92 Phase 1, 77 Phase 2, 69 Phase 3, 6 Not applicable, 6 Phase 4.
Follow Qilu Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer QL1203 + mFOLFOX6, Vectibix®+ mFOLFOX6 - RAS Wild-type Metastatic Colorectal Cancer | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 136 | 2026-11-24 | 2026-09-21 |
| A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma Iparomlimab and Tuvonralimab Injection (QL1706), Docetaxel, Oxaliplatin - Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 34 | 2026-11-01 | 2026-09-18 |
| Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation Romiplostim N01 - Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Henan University of Science and Technology | 87 | 2026-11-01 | 2026-09-21 |
| A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 556 | 2026-10-15 | 2026-09-03 |
| Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 35 | 2026-10-01 | 2026-09-15 |
| A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus) - Melanoma, Acral Melanoma | Phase 4 | Not yet recruiting | Peking University Cancer Hospital & Institute | 76 | 2026-10-01 | 2026-10-02 |
| Comparative Study of QL1209 and Perjeta® in Healthy Male Participants QL1209, US-Perjeta® - Breast Cancer | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 80 | 2026-10-01 | 2026-10-09 |
| QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ QLS31905, Sintilimab, Oxaliplatin - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 560 | 2026-09-24 | 2026-10-19 |
| The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia QLS2319, Placebo - Cancer Cachexia, Cancer Cachexia Syndrome | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 88 | 2026-09-16 | 2026-09-25 |
| A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases Ia:QLS2404 very low dose, Ia:QLS2404 low dose, Ia:QLS2404 middle dose - Systemic Lupus Erythematosus, Primary Sjögren's Syndrome | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 64 | 2026-08-11 | 2026-08-07 |
| Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) QLS7305 Injection - IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-08-10 | 2026-07-28 |
| QLF4113 in Participants With Metastatic Prostate Cancer QLF4113 for injection - Prostate Cancer | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 140 | 2026-07-20 | 2026-06-09 |
| Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients) Aflibercept Intravitreous Injection - Diabetic Macular Edema (DME) | Phase 4 | Not yet recruiting | The Third Peoples Hospital of Dalian | 186 | 2026-06-30 | 2026-05-29 |
| Phase II Study of QLC2519 in Pediatric Solid Tumor Participants Albipagrastim alf - Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN) | Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 18 | 2026-06-26 | 2026-07-24 |
| QLC5508 in Participants With Metastatic Prostate Cancer QLC5508, Docetaxel - Prostate Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 700 | 2026-06-20 | 2026-06-08 |
| Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction QLC5508 (Investigational Product / Formulation T), QLC5508 (Reference Product / Formulation R), Itraconazole - Refractory or Relapsed Solid Tumors | Phase 1 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 48 | 2026-06-09 | 2026-09-15 |
| A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy - TNBC, Adjuvant Therapy | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 59 | 2026-06-05 | 2026-06-03 |
| An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer Sunitinib、Olaparib、Tolilizumab - Ovary Cancer | Phase 2 | Recruiting | Bai-Rong Xia | 35 | 2026-06-01 | 2026-06-25 |
| To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3) QL2401 25 mg, QL2401 50 mg, QL2401 100 mg - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 132 | 2026-06-01 | 2026-06-02 |
| Study of QLS1410 in the Treatment of Primary Aldosteronism. QLS1410, Placebo - Primary Aldosteronism | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-06-01 | 2026-04-24 |
Showing 20 of 226. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (14) · Colorectal Neoplasms (7) · Multiple Myeloma (7) · Neoplasms (7) · Recurrence (7) · Uterine Cervical Neoplasms (7) · Breast Neoplasms (6) · Carcinoma, Hepatocellular (5) · Dermatitis, Atopic (5) · Prostatic Neoplasms (5) · Hepatitis B, Chronic (4) · Small Cell Lung Carcinoma (4) · COVID-19 (3) · Endometrial Neoplasms (3) · Hyperlipoproteinemia Type II (3)
Bevacizumab (14) · Carboplatin (13) · Cisplatin (12) · Oxaliplatin (12) · Capecitabine (11) · Paclitaxel (11) · Gemcitabine (8) · Dexamethasone (6) · Docetaxel (6) · Injections (6) · QL1206 (5) · pomalidomide (5) · 130-nm albumin-bound paclitaxel (4) · Denosumab (4) · Meropenem (4)
China (161) · Germany (1) · New Zealand (1) · United Kingdom (1) · United States (1)
Jinlin Hou, PhD (2) · Junqi Niu, PhD (2) · Li Zhang, Doctor (2) · Xiaoai He (2) · Xinghua Gao, Doctor (2) · Aili He, MD, PhD (1) · Anwen Liu, Ph.D. (1) · Baijun Fang, MD, PhD (1) · Baohui Han, PhD (1) · Binghua Wang, MD, PhD (1) · Caicun Zhou (1) · Caicun Zhou, MD, PhD (1) · Congmeng Lin, MD, PhD (1)
PMID 37158938, PMID 38054726, PMID 36819512, PMID 41045933, PMID 26269220, PMID 26687320, PMID 27902470, PMID 35087031, PMID 36802320, PMID 36829154, PMID 37936687, PMID 37987893, PMID 38112795, PMID 38130645, PMID 38280448, PMID 38282003, PMID 38906970, PMID 39276185, PMID 39529169, PMID 40353390, PMID 40642487, PMID 40650620, PMID 41209655, PMID 41778148, PMID 42551432, PMID 42820658